Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

Tokunaga, Ryuma; Imamura, Yu; Nakamura, Kenichi; Uchihara, Tomoyuki; Ishimoto, Takatsugu; Nakagawa, Shigeki; Iwatsuki, Masaaki; Baba, Yoshifumi; Sakamoto, Yasuo; Miyamoto, Yuji; Yoshida, Naoya; Oyama, Shinichiro; Shono, Toshiyuki; Naoe, Hideaki; Saeki, Hiroshi; Oki, Eiji; Watanabe, Masayuki; Sasaki, Yutaka; Maehara, Yoshihiko; Baba, Hideo

doi:10.1002/cam4.514

Cited by 28 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, this autoantibody panel potentially demonstrated a better diagnostic sensitivity for early stage EJA patients than markers CEA and CA19-9, which are major serum tumor markers in gastrointestinal cancers currently used in clinical practice. The positive rates of CEA and CA19-9 in EJA patients were reported to be only 20.3% and 12.9%, respectively, and these markers are elevated most commonly in advanced-stage patients [ 37 ]. Furthermore, PPV is very important for a test used in early detection of cancer.…”

Section: Discussionmentioning

confidence: 99%

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma

Chen

Guo

et al. 2018

Gastric Cancer

View full text Add to dashboard Cite

Background We previously found that autoantibodies against a panel of six tumor-associated antigens (p53, NY-ESO-1, MMP-7, Hsp70, PRDX6 and Bmi-1) may aid in early detection of esophageal squamous cell carcinoma. Here we aimed to evaluate the diagnostic value of this autoantibody panel in esophagogastric junction adenocarcinoma (EJA) patients. Methods Serum autoantibody levels were measured by enzyme-linked immunosorbent assay in a training cohort and a validation cohort. We used receiver-operating characteristics (ROC) to calculate diagnostic accuracy. Results We recruited 169 normal controls and 122 EJA patients to the training cohort, and 80 normal controls and 70 EJA patients to the validation cohort. Detection of the autoantibody panel demonstrated an area under the curve (AUC) of 0.818, sensitivity 59.0% and specificity 90.5% in training cohort, and AUC 0.815, sensitivity 61.4% and specificity 90.0% in validation cohort in the diagnosis of EJA. Measurement of the autoantibody panel could distinguish early stage EJA patients from normal controls (AUC 0.786 and 0.786, sensitivity 50.0% and 56.0%, and specificity 90.5% and 90.0%, for training and validation cohorts, respectively). Moreover, a restricted panel consisting of autoantibodies against p53, NY-ESO-1 and Bmi-1 exhibited similar diagnostic performance for EJA (AUC 0.814 and 0.823, sensitivity 53.5% and 60.0%, and specificity 90.5% and 93.7%, for training and validation cohorts, respectively) and early stage EJA (AUC 0.744 and 0.773, sensitivity 55.6% and 52.0%, and specificity 90.5% and 93.7%, for training and validation cohorts, respectively). Conclusions Autoantibodies against an optimized TAA panel as serum biomarkers appear to help identify the present of early stage EJA. Electronic supplementary material The online version of this article (10.1007/s10120-018-0894-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma

Chen

Guo

et al. 2018

Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…In line with the current literature, risk factors for tumor recurrence such as an increased ASA-score, elevated levels of CA 19-9, or an advanced tumor stage have been described [11,[25][26][27][28][29]. Whether postoperative complications like anastomotic leakage affect the incidence of tumor relapse is discussed controversially [12,13].…”

Section: Discussionmentioning

confidence: 89%

Prognostic Impact of Lymph Node Localization in Node-Positive Esophageal Cancer

Eichelmann¹,

Palmes²,

Kneifel³

et al. 2020

COR

View full text Add to dashboard Cite

Background: Recurrent disease remains a major problem for esophageal cancer. This study was designed to evaluate the impact of localization of lymph node metastasis for tumor recurrence following curative esophageal resection. Methods: 273 patients undergoing esophagectomy for esophageal cancer between 2005 and 2014 at the Department of General, Visceral and Transplant Surgery, University Hospital of Münster were included. Tumor characteristics, treatment details, postoperative course and patients' outcome, including time point and localization of recurrent disease, were analyzed retrospectively. The median follow-up was 46.3 months. Results: Median overall and disease-free survivals were 22.7 and 13 months, respectively. Tumor characteristics including presence and number of lymph node metastasis, and localization of lymph node metastases, paraesophageal, perigastric and intra-abdominal, had significant impact on both tumor recurrence (p<0.001, p=0.003, and p=0.001, respectively) and disease-free survival (p<0.001, p=0.001, and p<0.001, respectively). Univariate and multivariate analysis confirmed tumor stage, lymph node metastasis, G-, L- and V-category, and neoadjuvant treatment as independent predictors of tumor recurrence. Conclusion: The tumor stage and response to neoadjuvant treatment remain the most important prognostic factors. In addition, localization and the number of resected lymph node metastasis can provide important additional information.

show abstract

“…Other studies have shown that, CA125 was associated with the R0 resection rate [13], recurrence, peritoneal dissemination [14] and OS in unresectable advanced or recurrent GC patients [15]; CA199 was related to pN [7,[16][17][18] and pTNM stage [17]; and CA724 was related to the pathological stage and had a good diagnostic value for gastric cancer [19]. However, none of the patients in those studies underwent NCT.…”

Section: Discussionmentioning

confidence: 96%

“…Serum tumor markers play important roles in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. As studies have suggested, AFU was considered to be related to liver metastasis in colorectal cancer [4]; AFP was associated with prognosis in gastric cancer patients undergoing surgery alone [5]; preoperative CEA could predict the prognosis of GC patients with no lymph node metastasis [6]; CA199 was an independent prognostic factor in gastroesophageal junction (GEJ) cancer patients who experienced surgery alone [7]; the CA125 level was related to the degree of peritoneal dissemination and the existence of malignant ascites in GC patients with peritoneal metastasis [8]; and CA724 was correlated with pTNM stage in gastric carcinoma patients [9]. However, for GC patients who underwent NCT, the evidence of these markers is still insu cient.…”

Section: Introductionmentioning

confidence: 99%

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Tong

Zhao

Shan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Serum tumor markers including AFU, AFP, CEA, CA199, CA125 and CA724, are of great importance in the diagnosis, prognostic prediction and recurrence monitoring of gastrointestinal malignancies. However, their significance in gastric cancer (GC) patients with neoadjuvant therapy (NCT) is still uncertain. The aim of this study was to evaluate the predictive value of these six tumor markers in locally advanced GC patients who underwent NCT and curative surgery. Methods: In total, 290 locally advanced GC patients who underwent NCT and D2 radical gastrectomy were retrospectively analyzed. Data on their tumor markers before (pre-) and after (post-) NCT and pathological characteristics were extracted from the database of our hospital. The optimal cutoff values of the six tumor markers were calculated by the ROC curve and Youden index. Their predictive significance was analyzed and survival curves for overall survival (OS) were obtained by the Kaplan-Meier method. Associations between categorical variables were explored by the chi-square test or Fisher's exact test. Multivariate analyses were performed by the Cox regression model. Results: Pre- and post-CA199, -CA125 and -CA724 could predict overall survival (all P < 0.05), but only the change (diff-) of CA199 was related to prognosis (P = 0.05). In the multivariable analysis, pre- (P = 0.014) and post-CA724 (P = 0.036) remained significant, though diff-CA724 was not an independent prognostic factor (P = 0.581). In addition, pre- and post-CA199, -CA125 and -CA724 were associated with lymph node metastasis (N- vs N+) and pathological stage (Ⅰ-Ⅱ vs Ⅲ) (all P < 0.05). Moreover, post-CA724 was related to the vascular or lymphatic invasion (P = 0.019), while pre-CA724 was not (P = 0.082). However, AFU, AFP and CEA showed no association with survival (P > 0.05). Conclusions: CA724 is an independent factor for prognosis and could be used to predict ypN and ypTNM stage in locally advanced GC patients undergoing NCT and curative resection.

show abstract

Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

Cited by 28 publications

References 32 publications

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma

Prognostic Impact of Lymph Node Localization in Node-Positive Esophageal Cancer

CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Contact Info

Product

Resources

About